ARAY (Accuray Incorporated) Forward P/E Multiple

Official company branding of Accuray (ARAY)

Accuray Incorporated (ARAY) production of radiation systems is protected by robotics patents and complex certification procedures. The business relies on long-term customer service, which creates high barriers to entry for competitors. High equipment costs and strict clinic capital expenditure budgets form a closed ecosystem. The current P/E ratio is 0.00, which is corroborated by the price action chart reflecting the market valuation.

Accuray - ARAY Forward P/E Multiple (period 07/04/2022 - 11/12/2026)
Brand item of Accuray, Inc.

The long lifecycle of CyberKnife systems provides Accuray Incorporated (ARAY) with a stable stream of service revenues. The forward P/E ratio compares the current share price with expected earnings, determining the premium paid for future growth. By analyzing the company's forward P/E history, an investor can observe the search for market equilibrium. Sharp fluctuations in this metric signal an overvaluation or undervaluation of assets. This indicator objectifies the real cost of capital.

Competitors of Accuray Incorporated

Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Forward P/E Multiple aurabiosciences.com (AURA)|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|SLS - Projected Price to Earnings|Actuate Therapeutics, Inc - Forward P/E Multiple|Citius Oncology Inc (CTOR) - Projected Price to Earnings|HURA (tuhurabio.com) - Projected Price to Earnings|protaratx.com (TARA) - Forward P/E Multiple|Future Price to Earnings Fate Therapeutics|WHWK: Future Price to Earnings Multiple|Forward P/E Multiple TCRX|Forward P/E Multiple championsoncology.com (CSBR)|XBiotech - Projected Price to Earnings|CEL-SCI Corp. (CVM) - Projected Price to Earnings Ratio|OSTX: Projected Price to Earnings|Future Price to Earnings Multiple RADX (radiopharmtheranostics.com)|ARTV: Forward P/E Multiple|ANL - Market Cap to Projected Earnings|Future Price to Earnings Veru Inc.|Price to Future Earnings Ratio TPST (tempesttx.com)|Forward P/E Multiple XLO|Projected Price to Earnings renovarobio.com RENB|Future Price to Earnings Mural Oncology MURA|Kairos Pharma Limited (KAPA) - Projected Price to Earnings Ratio|OKUR - Future Price to Earnings|Future Price to Earnings Multiple GDTC (CytoMed Therapeutics)|curis.com (CRIS) - Future Price to Earnings|Price to Expected Earnings Ratio APLM (Apollomics)|Future Price to Earnings Tharimmune Corp|Projected Price to Earnings Ratio Advanced Biomed Corp ADVB|Future Price to Earnings Genprex, Inc. (GNPX)|CLDI (calidibio.com) - Future Price to Earnings Multiple|Forward P/E Multiple SBFM (Sunshine Biopharma, Inc.)|Forward P/E Multiple Xenetic Biosciences Inc. XBIO|SLRX: Projected Price to Earnings|Kitov Pharma - Market Cap to Future Earnings Ratio|AONC: Forward P/E Multiple|Projected Price to Earnings Ratio beigene.com (BGNE)|CKPT (Checkpoint Therapeutics, Inc.) - Forward P/E Multiple|Price to Future Earnings Ratio ELEV (elevationoncology.com)|Forward P/E Multiple ICAD|Forward P/E Multiple ikenaoncology.com (IKNA)|Future Price to Earnings Notable Labs, Ltd. NTBL|Future Price to Earnings Multiple VIRX|MorphoSys - Forward P/E Multiple|NAYA - Forward P/E Multiple|AAPGV (Ascentage Pharma Group Ltd) - Projected Price to Earnings